Wanbury Limited — Updates, 24-03-2025: Press Release

Wanbury Limited is launching two new products: a branded hematic iron tablet named "C-RED" and an API called Ketamine Hydrochloride. The C-RED iron tablet aims to address iron deficiency, especially among pregnant individuals, leveraging a liposomal formulation known for better absorption and reduced gastrointestinal side effects. Anemia affects over 40% of the Indian population, presenting a significant market opportunity.

Ketamine Hydrochloride, developed utilizing a cost-competitive process by Wanbury's in-house R&D team, meets international pharmacopoeia standards. With an annual demand exceeding 200 tons, it serves both human and veterinary markets, particularly as a sedative for surgical procedures. The company expects to commence exports of Ketamine to European markets this month. These launches reflect Wanbury's strategic focus on leveraging its expertise in the gynecology segment and expanding its product portfolio in high-demand areas. Investors should monitor these developments closely for potential growth opportunities.